Alpha 2.0
Login Register
» Authors » Johan Beetens

Johan Beetens

Explore the profile of Johan Beetens including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 50
Followers 0
Related Specialties
Pharmacology
Chemistry
General Medicine
Top 10 Co-Authors
Florence Namour
Piet Wigerinck
Helen Timmis
Frederic Vanhoutte
Tim Van Kaem
Annegret Van der Aa
Anton Megens
Sonia Dupont
Stefan Hartle
Jo Lambert
Published In
J Med Chem
Ann Rheum Dis
J Clin Med
Bioorg Med Chem
Br J Clin Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate-Severe Atopic Dermatitis
Thaci D, Singh D, Lee M, Timmis H, Jacobs D, Passier P, et al.
J Clin Med . 2022 Dec; 11(23). PMID: 36498818
Interleukin 17C (IL-17C) modulates epithelial inflammation and has a possible role in atopic dermatitis (AD) pathology. Four randomized clinical studies (Phase 1 and 2) investigated the safety, tolerability, efficacy, and...
2.
GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Timmis H, Van Kaem T, Desrivot J, Dupont S, Meuleners L, Beetens J, et al.
Clin Pharmacol Drug Dev . 2021 May; 10(9):994-1006. PMID: 33960725
GLPG1205 is a modulator of GPR84, a G-protein-coupled receptor reported to be associated with several diseases. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1205 in healthy subjects were evaluated in 2...
3.
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
Namour F, Galien R, Van Kaem T, Van der Aa A, Vanhoutte F, Beetens J, et al.
Br J Clin Pharmacol . 2016 Feb; 82(1):139-48. PMID: 26852904
Aims: Free fatty acids (FFA) can act as direct signalling molecules through activation of several membrane-bound G-protein coupled receptors. The FFA2 receptor (known as GPR43) is activated by short chain...
4.
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
Westhovens R, De Keyser F, Rekalov D, Nasonov E, Beetens J, Van der Aa A, et al.
Ann Rheum Dis . 2012 Nov; 72(5):741-4. PMID: 23161899
Background: Mitogen-activated protein (MAP) kinases are key regulators of cytokine production, and are therefore potential targets for treatment of rheumatoid arthritis (RA). Objective: This two-part phase II study investigated the...
5.
Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects
Namour F, Vanhoutte F, Beetens J, Blockhuys S, De Weer M, Wigerinck P
Drugs R D . 2012 Sep; 12(3):141-63. PMID: 22950522
Background And Objectives: GLPG0259 is a small-molecule inhibitor of mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5), a kinase enzyme that plays a role in important inflammatory pathways. The main objectives...
6.
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds
Baert B, Deconinck E, Van Gele M, Slodicka M, Stoppie P, Bode S, et al.
Bioorg Med Chem . 2007 Sep; 15(22):6943-55. PMID: 17827020
A set of 116 structurally very diverse compounds, mainly drugs, was characterized by 1630 molecular descriptors. The biological property modelled in this study was the transdermal permeability coefficient logK(p). The...
7.
Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines
Janssens F, Leenaerts J, Diels G, De Boeck B, Megens A, Langlois X, et al.
J Med Chem . 2005 Mar; 48(6):2154-66. PMID: 15771458
Clinical doses of available H(1) antihistamines are limited mainly by sedative side effects. However, higher doses are often required to obtain optimal therapeutic activity, especially in dermatology. We report the...